Effect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial
Introduction: Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for g...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2016-08-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/8365/20965_CE(EK)_F(AK)_PF1(NEAK)_PFA(AK)_PF2(PAG).pdf |
| Summary: | Introduction: Alendronate (ALN), an aminobisphosphonate,
inhibits osteoclastic bone resorption and also stimulates
osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an
osteoconductive graft material which provides a scaffold for
bone formation and also a widely used drug delivery vehicle
for growth factors and antibiotics. Drug delivery vehicles, like
β-TCP, improve the potency of the drugs by specific local site
delivery of the drug, optimal release characteristics and easy
handling.
Aim: The aim of the this study was to evaluate the bone
formation potential of 400µg ALN delivered in β-TCP in the
treatment of periodontal intra-osseous defects.
Materials and Methods: Thirty patients with periodontal
defects were randomly assigned to 400µg ALN + β-TCP + Saline
(test) group and β-TCP + Saline (active-control) group. Clinical
parameters like Clinical Attachment Level (CAL) gain, Probing
Depth (PD) reduction, post-operative Gingival Recession (GR)
were assessed from the baseline, 3 months and 6 months
recordings. Radiographic parameters like Linear Bone Growth
(LBG), Percentage Bone Fill (%BF), and change in alveolar
crest height (ACH) were assessed from baseline and 6 months
radiographs.
Results: Mean measurements in the ALN test group for CAL gain
(3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ±
0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater
with a p-value <0.05 compared to the mean measurements of
CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm),
LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control
group. There was mild alveolar crestal apposition (0.32 ± 0.68
mm) in the ALN test group and mild alveolar crestal resorption
(-0.24 ± 0.40 mm) in the control group.
Conclusion: 400µg ALN combined with β-TCP bone graft
material was effective in improving soft tissue parameters,
inhibiting alveolar crestal resorption and enhancing bone
formation, compared to β-TCP alone. |
|---|---|
| ISSN: | 2249-782X 0973-709X |